BiondVax Pharmaceuticals : Corporate Presentation – August 2020

The Universal

Flu Vaccine

Multi-Season

Multi-Strain

Flu Vaccine

CORPORATE PRESENTATION

AUGUST 2020

2

SAFE HARBOR STATEMENT

This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction.

All statements in this communication, other than those relating to historical facts, are "forward-looking statements" within the meaning of the United States Private Litigation Reform Act of 1995. You can identify forward-looking statements by terms including ''anticipates,'' ''believes,'' ''could,'' ''estimates,'' ''expects,'' ''intends,'' ''may,'' ''plans,'' ''potential,'' ''predicts,'' ''projects,'' ''should,'' ''will,'' ''would,'' and similar expressions intended to identify forward- looking statements. These forward-looking statements relate to our business and financial performance and condition, as well as our plans, strategies, objectives and expectations for our business, operations and financial performance and condition. However, these forward-looking statements are not guarantees of future performance and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, among others: the risk that drug development involves a lengthy and expensive process with uncertain outcome; BiondVax's ability to successfully develop and commercialize its vaccine; the length, progress and results of any clinical trials; the introduction of competing products; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals to commercialize BiondVax's products; the difficulty in evaluating business prospects; the adequacy of available cash resource and the ability to raise capital when needed; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; changes in the global pharmaceutical industry; changes in customers' budgeting priorities; European Medicines Agency and other regulatory authority approvals; natural disasters; labor disputes; rising interest rates; general market, political or economic conditions in the countries in which we operate; pension and health insurance liabilities; volatility or crises In the financial market; arbitration, litigation and regulatory proceedings; and war or acts of terror.

Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. You should not unduly rely on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 20-F for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC. Readers are urged to carefully review and consider the various disclosures made in the Company's SEC reports, which are designed to advise interested parties of the risks and factors that may affect its business, financial condition, results of operations and prospects. These forward-looking statements speak only as of the date of this presentation, and we assume no obligation to update or revise these forward-looking statements for any reason, whether as a result of new information, future events or otherwise, except as required by law.

One • For All : The Universal Flu Vaccine

3

BIONDVAX ON THE RADAR

More News: http://www.biondvax.com/press-releases/in-the-news/

One • For All : The Universal Flu Vaccine

4

A SEASONAL PROBLEM… A PANDEMIC THREAT

The Flu: A Serious Public Health Challenge

SEASONAL FLU - DESPITE ANNUAL VACCINE PRODUCTION (500 MILLION DOSES1)

Flu cases:	Severe illness:	Deaths:
up to 20%2
3 - 5 million3	650,0003
or 1.5 billion

• At-riskSeniors: 89% of deaths & most hospitalizations4
• High economic burden: Over $361B in the USA4
• USA: Up to 80,000 deaths and 900,000 hospitalizations5

PANDEMIC FLU

• New pandemic strain: When?… Where?... Which?
• Higher morbidity & mortality worldwide
• Estimated cost in US $413B to $3.79T4

1 WHO: http://www.who.int/influenza_vaccines_plan/objectives/objective2/en/ and https://en.wikipedia.org/wiki/Influenza_vaccine#Uptake; 2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596521/;

3 WHO: http://www.who.int/news-room/detail/14-12-2017-up-to-650-000-people-die-of-respiratory-diseases-linked-to-seasonal-flu-each-year (varies annually); 4 White House Council of Economic Advisors (CEA), Mitigating the Impact of Pandemic Influenza through Vaccine Innovation, September 2019.; 5CDC: www.cdc.gov/flu/about/disease/burden.htm and https://www.nytimes.com/2018/10/01/health/flu- deaths-vaccine.html

5

CURRENT VACCINE FALLS SHORT: THE MISMATCH

The Flu Virus: Frequent and Unpredictable Mutations

Why current solutions fall short…

• Past strains selection → Mismatch phenomenon
• Previous season's vaccine will not necessarily protect against next season's flu strains
• 4-6month production lag

Seasonal Flu Vaccine Effectiveness1

Average 40%, Elderly as low as 9%2

2004-05	10%
2005-06	21%
2006-07	52%
2007-08	37%
2008-09	41%
2009-10	56%
2010-11	60%
2011-12	47%
2012-13	49%
2013-14	52%
2014-15	19%	100%
2015-16	48%	Protection
2016-17	40%
2017-18	38%
2018-19	29%

Measles, Rubella, Diphtheria, Tetanus, etc. 95%-99%

1. VE data: CDC, including https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm [Retrieved 29 October 2019]
2. World Health Organization: http://www.who.int/immunization/research/meetings_workshops/2a_Graham_pdvac_sept14.pdf

6

THE ELDERLY - AT RISK AND IN NEED

• ~80% of seasonal flu related death occurs in elderly1
• Seasonal vaccine effectiveness as low as 9% for elderly2
• 80% of older adults have at least one chronic condition3
• Influenza worsens outcomes of chronic illness
• Elderly flu cost in US estimated4 at $56B per year

(hospitalization, mortality, lost earnings)

NIH: "During the period from 1989 to 1997 the vaccination rate for elderly persons ≥65 years of age in the US increased from 30 to 67%. Despite this increase in coverage, mortality and hospitalization rates continued to increase rather than decline as would be expected..."

International Journal of Epidemiology5 (Vol. 35, Issue 2, P352-353)

1. Vaccine journal: www.sciencedirect.com/science/article/pii/S0264410X15002315, Table 3; 2 WHO: http://www.who.int/immunization/research/meetings_workshops/2a_Graham_pdvac_sept14.pdf

1. https://www.ncoa.org/healthy-aging/chronic-disease/;4 Molinari et. al, The annual impact of seasonal influenza in the US, Vaccine 25 (2007) 5086-5096;5 https://academic.oup.com/ije/article/35/2/352/694736;

7

MEETING MILESTONES & CATALYSTS

Solid Science, Phase 3 Clinical Stage, Strong IP

							Ongoing Pivotal Clinical
Technology developed							Efficacy Phase 3 trial
	TASE June 2007		Nasdaq: BVXV		Commercial
by Prof. Ruth Arnon				(Europe)
Head BiondVax's SAB		Delisted 2018		2015		pilot facility

2005

Mid 90's					2020
		BiondVax			7 Successful Clinical Trials
		operational		•	Two Phase 1/2 & Five Phase 2
				•	Israel, Europe, USA (NIH)	.

• FDA IND / EMA SA

Co-Inventor of	• 818 young adult to elderly participants
• M-001 shown to be safe and
	immunogenic in all studies

One • For All : The Universal Flu Vaccine

8

M-001:A COMMON DENOMINATOR OF FLU VIRUSES

)	PucleoNrotein(NP)	AemHgglutinin(HA)
proteinatrixM (M
1

Now in prefilled syringes

Target Common Regions: Nine common flu regions (epitopes) connected to make one recombinant protein (M-001) produced in E.coli

BiondVax's M-001 Key Advantages	Existing vaccines
Universal: Broad coverage types A&B	Strain specific
Single formulation enabling	New vaccine every
year-round vaccination	year
Quick, robust year-round production	Long (4-6 month)
through E.coli fermentation (6-8 weeks)	production cycle
Induces cellular (CMI) and enhances	Limited vaccine
humoral (HAI priming effect) immune
effectiveness
response to flu
Shelf life up to 24 months at 2-8⁰C	Not applicable, since
(testing is ongoing) and 6 months at ~25⁰C	new vaccine every
(room temperature)	season

One • For All : The Universal Flu Vaccine

9

M-001:THE UNIVERSAL FLU VACCINE

M-001's dual mode of action potentially offers multi-season and multi-strain protection

• Flu viruses are intracellular parasites
• Most of their lifecycle occurs inside our cells, thus are out of the reach of antibodies
• Our immune system mainly fights viral infection with cellular immunity via cytokines

Our immune system has 2 arms:

	Cellular (CMI)				Humoral (HAI)
Works inside infected cells	BiondVax's M-001		Works outside cells
	T-cell		Dual Mode of Action		B-cell
	Directly		T-cell
		induces		priming
e.g. T-Helper, CD4, CD8	T-Cells		effect	Produce
		enhances
Produce anti-viral			Antibodies
		B-Cell
cytokines such as
		responses
IL-2	IFN-g

Current vaccines mainly induce only flu strain-specific antibodies

One • For All : The Universal Flu Vaccine

10

ADVANCED CLINICAL DEVELOPMENT

M-001: Safe and Immunogenic in Young Adults to Elderly

• No treatment-related severe adverse events
Group	Day 0	Day 21	Day 42
• Adverse events were mild to moderate
Treatment	M-001	M-001	Seasonal or Pandemic HA
• All adverse events observed were transient
Control	Saline	Saline	vaccine to all participants
• Immunity: Cellular induced, humoral enhanced	Baseline		CMI	HAI
Phase	Trial	Year	Population (age)	Total			Results
Participants
1/2	BVX-002	2009	Younger Adults (18-49)	63
1/2	BVX-003	2010	Older Adults (55-75)	60	M-001 was well tolerated and a cellular
2	BVX-004	2011	Younger Adults (18-49)	200		(CMI) and humoral (priming effect)
2	BVX-005	2012	Elderly (65+)	120		immune response was observed
2	BVX-006	2015	Older Adults (50-65)	36
2b	BVX-007a	2015-16	EU Adults (18-60)	219
2	BVX-008b	2018	USA Adults (18-49)	120	Safe and significant T cell responses
				818
3	BVX-010	2018	E. European Adults (50+)	12,463	Results expected by end of Oct. 2020

1. BVX-007was conducted in collaboration with the EU's UNISEC consortium.

b BVX-008 conducted and led by NIAID/NIH. Clinical study report submitted June 2020.

11

M-001:INDUCES CELL MEDIATED IMMUNITY (CMI)

Direct Evidence: CD8, CD4 T-cell Activated Cells Produce TH1 Cytokines (IFN-gamma,IL-2 & TNF-alpha)

BVX0051: CD4 & IFN-gamma in Elderly

SE)+

0.3

M-001 twice Day 0

**

0.25

*

*

M-001 twice Day 42

(Mean

0.2

cells

0.15

*

*

0.1

positive%

0

0.05

A/Brisbane/10/07 A/California/7/09

A/Perth/16/09 B/Brisbane/60/08 Flumist 2011

H3N2

H1N1

H3N2

% positive cells (Mean + SE)

BVX0051: CD8 & IFN-gamma in Elderly

0.3

*

M-001 twice Day 0

*

M-001 twice Day 42

0.25

0.2

0.15

0.1

* P<0.05

0.05

**P<0.07

0

A/Brisbane/10/07

A/California/7/09

A/Perth/16/09 B/Brisbane/60/08

Flumist

H3N2

H1N1

H3N2

UNISEC (EU): Statistically significant anti viral cytokines NIAID/NIH: "M-001 induced significant polyfunctional T cell responses"

placebooverchangeFold	10																	* P<0.05				SubsetsCellTCD4+%Mean MarkersExpressing	0.015
0																									0
	8			6.8*				5.3*															0.01			Placebo		M-001
	6			3.8			4.7
	4																						0.005
	2																	0.4*	-0.2
M-001:	1mg 0.5mg	1mg	0.5mg	1mg 0.5mg										Baseline				Day 36
			IFN-gamma			IL-2						TNF-alpha												IL-2 + TNF-alpha + IFN-gamma

Sources:

• BVX005: Jacob Atsmon et al. Priming by a novel universal influenza vaccine (Multimeric-001)-A gateway for improving immune response in the elderly population. Vaccine 32 (2014) 5816-5823
• NIAID/NIH-supportedPhase 2 BVX008 clinical trial: https://clinicaltrials.gov/ct2/show/results/NCT03058692 & Clinical Study Report

* P<0.001

12

M-001:ENHANCES HUMORAL IMMUNITY (HAI)

Indirect Evidence: Extending T-Cell Priming Effect for Enhanced HAI Responses to Current Flu Vaccines

BVX0051: 2011/12, age 65+ YO

	70	*
Seroconversion	60							TIV		Twice M-001 + TIV
50
40
30
20

"M-001 can provide broadened enhanced immunity extending even to influenza strains destined to circulate in future years." - Vaccine 2

%	10
	0

A/California/7/09 A/Perth/16/09 B/Brisbane/60/08

H1N1 pandemic swine flu

BVX003: 2009, age 55-75 YO

	80							TIV			Twice M-001 + TIV
seroconversion	70
60
50
40
30
20
%
	10
	0

In 2011 we

administered M-001 to seniors 65+ (BVX005)

4 years later, 5 times more seniors were seroprotected from a new epidemic strain (A/Swiss) that didn't exist in 2011!

	70
		*
(HAI)	60
50
% Seroprotection	40
30
20
10
	0
	TIV 2011/12	M-001 & TIV 2011/12

A/Brisbane/59/07

A/Brisbane/10/07

B/Brisbane/60/08

* P<0.05

1. Jacob Atsmon et al. Priming by a novel universal influenza vaccine (Multimeric-001)-A gateway for improving immune response in the elderly population. Vaccine 32 (2014) 5816-5823
2. Lowell GH et al. Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain. Vaccine (2017)

13

PIVOTAL CLINICAL EFFICACY PHASE 3 TRIAL (EUROPE)

1. pivotal, multicenter, randomized, modified double-blind,placebo-controlled phase 3 trial to assess the safety and clinical efficacy of M-001, an influenza vaccine, administered intramuscularly

twice in older adults and the elderly (≥50 years of age)

Trial Design:	Cohort 1 (4,042 enrolled & randomized Aug-Oct 2018)
Flexible	Cohort 2 (8,421 enrolled & randomized July-Nov 2019)
enrollment
Day 1	Day 21	Day 202	~12,400 participants
				Age 50+ (half 65+)
Experimental	1mg M-001	1mg M-001
Safety, RT-PCR or
			Two flu seasons
			culture on any ILI
Control	Placebo	Placebo	(during flu season)	Results by end of
				October 2020

• ILI symptoms active surveillance throughout both flu seasons
• Primary endpoints: Safety & clinical efficacy by reduction of illness rate
• Secondary endpoint: Reduced severity of influenza illness

Professor Shai Ashkenazi, MD

BiondVax's Medical Director

• Dean of Medicine, Ariel University
• Former Director of Pediatrics at Schneider Children's Medical Center of Israel
• Former Lea and Arieh Pickel Chair for Pediatric Research, Sackler Faculty of Medicine
• Experienced clinician-researcher; guided vaccines through clinical and regulatory approval to market

One • For All : The Universal Flu Vaccine

14

BIONDVAX'S NEW MANUFACTURING FACILITY

From Lab to Pilot Mid-Size Commercial Scale Facility

• Funding: EIB, BiondVax, and Israel's Ministry of Economy & Industry
• Target annual capacity: Up to between 10 and 20 million doses in bulk
• Goal: Year-round GMP production & stockpile per market demand

Jerusalem BioPark

Hadassah Ein Kerem Campus

Jerusalem, Israel

One • For All : The Universal Flu Vaccine

					15
BIONDVAX: FIRST-IN-CLASS, BEST-IN-CLASS
			Phase
Player	Technology	Pre-	I	II	Status
		clinical	III
BiondVax	M-001: Synthetic protein B- & T-cell peptides (HA, M1,				Statistically significant European Ph2b trial UNISEC
			consortium. NIAID/NIH sponsored ongoing collaboration
	NP). Broad coverage, 6 completed clinical trials in adults	N=13,281
		Phase 2 in USA.
	18 to 65+
				Ongoing pivotal, clinical efficacy Phase 3 trial (Europe).
Imutex +	FLU-V: 4 T-cell peptides adjuvanted formulation				2016: Seek created Imutex with hVIVO
N=408			2020: hVIVO acquired by Open Orphan (AIM: ORPH)
	Challenge and immunogenicity trials
				Phase 2 trials (field, challenge) positive results
	M2SR (RedeeFlu): Single replication virus; Broadening				Phase 2 challenge, intranasal, 2019 interim results
	immunogenicity to flu sub type H3N2.	N=389			'serum antibody response.' Equity funding $27m,
	First in human results reported 2018. Immunogenic in			including $5.5m Aug 2017; $27m gov't grants.
	mice				NIAID sponsored Phase 1, began 2019.
					2019: Phase 1 CD8 T Cell response. Phase 2a results
	OXV836: Recombinant poly-Arg NP (H1 strain) in VLP,	N=372			expected 2021. Raised total €14.3m + up to €32.6m
	produced in E.coli. CD8 T-cell activation			grants and equity (also towards corona vaccine
					candidate, 2020).
					Phase 1 interim results (2019), elicited cross reactive
	Chimeric H1 targeting stalk of group 1 (H1,H2,H5)	N=108			anti-stalk serum IgG antibodies. NIAID-sponsored Phase
					1 in children.
	H1ssF_3928: H1 HA stem + ferritin nanoparticle.	N=70			Phase 1 began 2019, results expected 2020.
	NIH infrastructure
Academic labs	Stem-only immunogens based on rational design; DNA
	and RNA vaccines. Heterosubtypic protection in mice,				Results in animals.
	ferrets, primates

One • For All : The Universal Flu Vaccine

Based on publicly available information. Last updated February - July 2020

16

SUMMARY FINANCIAL DATA

• Lean structure with 25 employees. Manufacturing scale-up and operating burn ~$700K/month
• Fully funded through end of ongoing Phase 3 clinical trial:
• • €24M EIB non-dilutiveco-funding agreement1
  • Rights offering July 2019, $20M gross proceeds2
  • Secondary offering Sept 2017, $10M gross proceeds
  • Government of Israel support from Ministry of
    Economy and Industry's Israel Investment Center, and royalty-based grants from the Israel Innovation Authority (formerly Office of the Chief Scientist)

American Depository Shares ticker:

BVXV

1 European Investment Bank (EIB) €24M support for M-001 Phase 3 trials and commercial production also includes:

• Milestone based drawdowns received in 2018 and 2019
• Zero-percentfixed interest loan for five years after each of the 4 drawdowns
• Variable remuneration based on royalties of net sales

2 http://www.biondvax.com/2019/07/biondvax-announces-rights-offering-fully-subscribed-at-us20-million/

17

FLU VACCINES - A LARGE AND GROWING MARKET

The Big Four Flu Vaccine 2019 Revenue

Flu Vaccine Market

Seasonal Flu

1. Worldwide: Up to $5.2B global market in 2018;

	$0.69B6
	GSK
$0.11B9	17%
	3%

Seqirus

29%

$1.20B8

2014/5: CSL bought Novartis' Flu vaccine unit, rebranded to Seqirus

Sanofi

51%

$2.12B7

2017: Acquired Protein Sciences for $750M

expected to grow to $7.5B by 20241

1. USA: $2.6B in 20192; ~174M doses in 2019/2010 o Forecasted CAGR of 6.37%1

Pandemic Flu

1. Swine Flu (A/H1N1) 2009 + first half of 2010 sales: $5-6B worldwide by Novartis, GSK and Sanofi (on top of seasonal flu vaccine sales)4

1. >1B pandemic vaccines doses ordered in 200911

"The United States has spent approximately $1 billion in these [H5N1 flu vaccine stockpile] efforts to date."5

"…part of our nation's overall pandemic preparedness strategy…stockpile of bulk vaccine…for influenza viruses with pandemic potential to vaccinate 26 million people immediately after a pandemic is declared."12

1. https://www.researchandmarkets.com/research/5q8dvw/ (2) https://www.coherentmarketinsights.com/market-insight/us-influenza-vaccines-market-1127(3) https://www.marketwatch.com/press- release/united-states-influenza-vaccine-market-size-global-industry-analysis-segments-top-key-players-drivers-and-trends-to-2022-2019-02-27(4) www.vaczine-analytics.com/ER_January_100128s.pdf(5) http://www.who.int/immunization/sage/meetings/2013/november/SAGE_WG_H5vaccine_background_paper_16Oct2013_v4.pdf (6) https://www.gsk.com/en-gb/investors/corporate-reporting/annual-report-2019#tab-1-4 [At exchange rate 1.28] (7) https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-06-07-30-00 [At exchange rate 1.12] (8) YE June 2019 https://medialib.csl.com/- /media/shared/documents/results/2019-fy-analyst.pdf(9) https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2018/PDF/AstraZeneca_AR_2018.pdf,page 69. Likely less than $0.11B in 2019, was not detailed in AZ FY19 annual report (10) https://www.cdc.gov/flu/prevent/vaccine-supply-distribution.htm(11) https://www.theglobeandmail.com/life/health-and-fitness/health/conditions/how-vaccines-became-big-business/article572731/(12) https://www.phe.gov/ASPRBlog/Lists/Posts/Post.aspx?ID=322

18

MANAGEMENT

Ron Babecoff	Tamar	Uri Ben-Or	Elad Mark	Joshua Phillipson
Ben-Yedidia
DVM, MEI	CPA, MBA	BSc Engineering, MBA	Hon. BSc, MBA
PhD
Founder,	CSO & Clinical Trial	CFO	COO	Director of Business
President & CEO	Leader	Development & IR
• DVM (University of Liège)	• Co-inventor of the universal	• BA Business (College of	• BSc. Engineering (Afeka Tel	• Hon. BSc. (University of
• Master in Entrepreneurship &	flu vaccine	Administration)	Aviv College of Engineering)	Toronto)
Innovation (ISEMI, Swinburne)	• PhD (Weizmann Institute of	• MBA (Bar Ilan University)	• MBA (Open University of Israel)	• MBA (Ben Gurion University
• Omrix Biopharmaceuticals Ltd	Science)	• Certified Public Accountant	• Principal bioprocess engineer	of the Negev)
• Biotechnology General Ltd.
(Marketing Manager)	(CPA)	• Novartis (Technical Project	• Accenture (Business
• Dexcel Pharma (Regional		• Glycominds Ltd. (VP	Manager - Process)	Management Consultant)
Export Manager)		Finance)		• BioData Ltd. (Marketing
		• Menorah Capital Markets		Manager)
		(Comptroller)

One • For All : The Universal Flu Vaccine

19

BOARD OF DIRECTORS

Mr. Mark Germain	Aentib Group (Managing Director), Pluristem (Director). Founder, director, chairman,
Chairman of the Board	and/or investor in over twenty biotech companies
Ron Babecoff, DVM, MEI	Omrix Pharmaceuticals Ltd (Marketing Manager), Dexcel Pharma Technologies Ltd.
Founder, President and CEO	(Formerly Dexxon, Regional Export Manager)
Mr. Isaac Devash, MBA	Credit Suisse First Boston (Investment Banking), Private equity and venture capital funds
Director	(Founder)
Dr. Morris C. Laster, MD	BioLineRx (CEO, Director), OurCrowd (Partner), Clil Medical (CEO), Vital Spark (CEO),
Director	Kitov Pharmaceuticals (Co-founder, Director)
Dr. George Lowell, MD	ID Biomedical (CSO), Intellivax (Founder), Walter Reed General Hospital (Consultant)
Director
Dr. Yael Margolin, PhD	Gamida Cell Ltd. (Nasdaq: GMDA) (President, CEO, Director), Denali Ventures LLC (VP)
External Director
Mr. Samuel Moed	Bristol Myers Squibb (NYSE: BMY) (Senior Vice President, Corporate Strategy)
Director
Mr. Adi Raviv, MBA	Capacity Funding LLC (Principal)
External Director
Prof. Avner Rotman, PhD	Biodar (CEO), Rodar (Founder), Israel Biotech Organization (Chairman, Steering
Director	committee)
Dr. Ruth Ben Yakar, PhD	BioSight Ltd (CEO, Director), SHL Telemedicine (Director), Cellect Biotechnology (Director)
Director

One • For All : The Universal Flu Vaccine

					20
CAP TABLE
	Nasdaq: BVXV	ADS	%	ADS	Expiration
	July 15, 2020	Outstanding	Price	Date
	Ordinary ADS	11,520,566	95%
	Options + RSUs	599,902	5%	Variable	Variable
	Fully Diluted Shares	12,120,468	100.00%
	Outstanding

• Voluntarily delisted from Tel Aviv Stock Exchange January 22, 2018. (ADS-Shares 1:40 ratio)
• Warrants issued to investors in connection with BiondVax's IPO on Nasdaq in 2015 and traded under symbol BVXVW expired in May 2020.

One • For All : The Universal Flu Vaccine

21

IP: COMPREHENSIVE AND EXPANDING COVERAGE

• 74 Patents & 11 Pending Applications
• Covering polypeptides, polynucleotides, compositions, uses, formulations, production
• Expiration to 2035

Title	International	Subject Matter	Priority &	Status	Expiry
(updated: March 2020)	Publication	Assignee
Peptide-Based Vaccine for		Vaccine comprising	11/30/1998: Yeda	Granted: USA
WO 00/032228	different epitopes of	R&D licensed to	Expired: 1, 3, 5, 12, 13, 15, 19, 20,	USA: Aug 2020
Influenza
	the virus	BiondVax	22, 24, 25, 26, 31, 33, 35, 36
		Wide-range vaccines	12/6/2005: Yeda R&D	Granted: 1, 2, 3, 5, 9, 12, 13, 14, 18,	Dec 2026
Improved Influenza Vaccine	WO 2007/066334	- broad strain and
licensed to BiondVax	19, 20, 23, 25, 28, 31, 32, 33, 35, 36	USA: Jan 2027
		extended protection
		Vaccines comprising		Granted: 1, 2, 3, 4, 5, 6, 7, 8, 9, 11,	Aug 2028
Multimeric Multi-Epitope Influenza		multiple copies of		12, 13, 15, 16, 17, 18, 19, 20, 21, 22,
WO 2009/016639	8/2/2007: BiondVax	Brazil: Nov 2029
Vaccines	several epitopes -	23, 24, 25, 27, 28, 29, 30, 31, 32, 33,
		USA: Aug 2031
		current product		34, 35, 36
Multimeric Multi-Epitope		Use of Multimeric as			Feb 2031
Polypeptides in improved Seasonal	WO 2012/114323	a primer to	BiondVax	Granted: 1, 5, 36
USA: May 2031
and Pandemic Influenza Vaccines		conventional vaccines
Vaccine Compositions of		Production &		Allowed: 1, 21, 36
Multimeric Multi-epitope Influenza	WO 2015/151103	4/3/2014: BiondVax	April 2035
formulation	Pending: 5, 6, 10, 15, 17, 19
Polypeptides and their Production

1=Australia, 2=Austria, 3=Belgium, 4=Brazil, 5=Canada, 6=China, 7=Croatia, 8=Czech Republic, 9=Denmark, 10=Europe, 11=Finland, 12=France, 13=Germany, 14=Greece, 15=Hong Kong, 16=Hungary, 17=India, 18=Ireland, 19=Israel, 20=Italy, 21=Japan, 22=Korea, 23=Luxembourg, 24=Mexico, 25=Netherlands, 26=New Zealand, 27=Poland, 28=Portugal, 29=Romania, 30=Russia, 31=Spain, 32=Sweden, 33=Switzerland, 34=Turkey, 35=UK, 36=USA.

The Universal

Flu Vaccine

Multi-Season

Multi-Strain

Flu Vaccine

CONTACT INFORMATION:

JOSHUA PHILLIPSON

[e-mail] [phone]

www.biondvax.com